School of Life Sciences, Shanghai University, Shanghai 200444, People's Republic of China

*Corresponding author: Da-Yong Lu, School of Life Sciences, Shanghai University, Shanghai 200444, People's Republic of China, Email: [email protected].

Received Date: December 08, 2022

Published Date: December 15, 2022

Citation: Lu DY, et al. (2022). Anti-Metastatic Drug Developments, Utility of More Animal Models. Mathews J Pharma Sci. 6(1):11.

Copyrights: Lu DY, et al. © (2022).

ABSTRACT

Neoplasm metastasis is a multiple-step and multi-molecular pathogenesis process resisting to current norm of therapeutics. More seriously, there is a great shortage of effective and licensed anti-metastatic drugs worldwide. Several evaluative avenues of pharmaceutical efforts might change this scenario in the future. Preclinical tumor models in vivo are workable to embrace new therapeutic strategies and paradigms in the clinic. This Editorial provides latest views of advanced metastatic models in vivo and possible breakthroughs in drug evaluation and development.  

Keywords: Neoplasm Metastases, Cancer Chemotherapy, Clinical Cancer Trial, Personalized Medicine, Animal Model, Brain Metastasis.